CrossBridge Bio is an innovative company focused on developing Antibody-Drug Conjugates (ADCs) with a platform that emphasizes stability, precise drug release, and mitigation of off-target effects. The company aims to revolutionize cancer therapeutics through its advanced technology and diverse antibody-payload pairings.

CrossBridge Bio

CrossBridge Bio | 903 followers on LinkedIn. CrossBridge Bio is a biotechnology company focused on developing innovative dual-payload ADC therapeutics. | CrossBridge Bio is a biotechnology company focused on developing innovative ADC therapeutics using our proprietary stable dual-linker payload technology.

Translational Oncology | Drug Discovery | In Vivo and In Vitro Pharmacology | Neuro Immunology I Neurodegeneration | Project Management & Research…

Veerakumar B.

Entrepreneur. Drug Developer. Doer.

Michael Torres

Biotech | VC | Investor

Damir Illich

Interesting coverage of CrossBridge Bio and their dual payload antibody-drug conjugates. The company will advance its lead candidate, the dual-payload ADC CBB-120 for the treatment of trophoblast cell-surface antigen 2 (TROP-2)-positive solid tumors, to investigational new drug (IND)-enabling studies. Safety testing in non-human primates is expected to start in 2025. We look forward to news in the future. #mabs https://lnkd.in/ebk-GJhJ

The Antibody Society

We're proud to announce non-dilutive funding to support CBB-120, our dual-payload ADC for Trop2+ cancers. Beyond CBB-120, we're building out our pipeline/platform and working with clinicians such as David S. Hong, MD & Martin Dietrich, MD, PhD , to ensure we build best-in-class assets to serve patients best. We're proud to be building here in #Texas ! Thank you Cancer Prevention and Research Institute of Texas for your support. Please reach out to our leadership team to learn more about investing/partnering opportunities: Michael Torres Daniel Pereira Abhishake Chhibber

I'm excited to share the story of building CrossBridge Bio with Kyoji Tsuchikama at #ASPET2024 . It all started with great science, in this case, Kyoji's novel linker that allows dual-payload ADCs. With great science, you need a great team. I'm privileged to have recruited folks like Daniel Pereira Morris Rosenberg Abhishake Chhibber to the team. More to come on the investor side of things, but suffice it to say, my team is thoughtful in utilizing our technology. It's attracting the right eyes! I look forward to sharing more!

We're looking forward to attending #ASCO24 this year. Don't hesitate to get in touch with our CEO ( Michael Torres ) and CSO ( Daniel Pereira ), who will be attending the conference. We look forward to catching up with old friends and sharing our updates.

Our CSO, Daniel Pereira , will be attending #AACR24 . Reach out if you’d like to connect and learn more about the exciting research and drug development happening here at CrossBridge Bio . We’re building an exciting pipeline using our ADC platform. You’ll see the full team at #ASCO .

Our scientific co-founder's ( Kyoji Tsuchikama ) review article on next-gen #ADCs is featured on the front cover of Nature Review Clinical Oncology's latest issue! The review article is free to access and download until the end of #AACR24 (April 11)! https://lnkd.in/dGCM_Sv2 #cancerresearch #cancerawareness #drugdiscovery #nextgenADCs

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 6, 2024 10:48 PM	daf17fbc
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 6, 2024 10:48 PM	8620e2b6
crunchbase trigger	general	Nov 6, 2024 10:48 PM	85257912
crunchbase profile	general	Nov 7, 2024 4:55 PM	ca891086
li profile	general	Nov 6, 2024 10:48 PM	3125c135
translate crunchbase fundingrounds	general
peers	general	Nov 6, 2024 10:48 PM	a6e8cb55
news basic	general	Nov 6, 2024 10:48 PM	a7756773
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

CROS

COM:CROSSBRIDGEBIO

CrossBridge Bio